Through the IQVIA Accelerator Program, Closed Loop Medicine will get the opportunity to harness IQVIA’s leading expert panel, insights and digital ecosystem
London, UK, 1st October 2023: Closed Loop Medicine Ltd., a leading TechBio company developing combination prescription drug plus software therapy products that enable personalized dose optimization, is pleased to announced that it is among ten start-ups taking part in the IQVIA Accelerator Program 2023, aiming to expedite growth of disruptive innovators in the healthcare market.
The eight-week IQVIA Accelerator Program, connects early-stage companies with the IQVIA ecosystem to drive faster solutions to market in key areas such as patient solutions, online marketplaces, remote devices, health management solutions, medical education, and research / clinical trials solutions. With a mix of classroom-based courses, workshops and mentoring sessions, participants will get the opportunity to expand their network, work with IQVIA world-class global experts, access IQUVIA’s unique assets and collaborate with clients across the healthcare ecosystem. As part of the program, the cohort companies will get the opportunity to develop bespoke “go-to-market” strategy which further supports commercial success and sustainable patient care.
Dr. Hakim Yadi OBE, CEO & Co-Founder of Closed Loop Medicine, said: “IQVIA is a global healthcare company working at the interface of technology, life sciences and care. This Accelrator stands out as it not only support the developeent and validation of our offering but also points to new ways of deploying a go-to-market offering for our products. We are looking forward to working with IQVIA and their global clients in maximizing the potential for dose optimsiation.
For further information, please visit: https://www.iqvia.com/about-us/innovation-hub/iqvia-accelerator-program